Close to 120 companies across the globe claim to possess the required expertise (Roots Analysis) Knowpia

Development initiatives of HPAPIs and cytotoxic drugs are generally very demanding, both in terms of experience and capital investment. Most companies generally lack the necessary resources to meet the aforementioned requirements and are unable to set up dedicated HPAPI and cytotoxic drug manufacturing facilities. This has led to an increased demand for contract manufacturing service providers in this field.

To order this 300+ page report, which features 75+ figures and 150+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/hpapi-and-cytotoxic-drugs-manufacturing/299.html

The USD 25 billion (by 2030) financial opportunity within the HPAPI and cytotoxic drugs contract manufacturing market has been analyzed across the following segments:

§ Type of Product

§ HPAPIs

§ Highly Potent Finished Dosage Forms

§ Company Size

§ Small-sized

§ Mid-sized

§ Large / Very Large

§ Scale of Operation

§ Preclinical / Clinical

§ Commercial

§ Type of Pharmacological Molecule

§ Small Molecules

§ Biologics

§ Type of Highly Potent Finished Dosage Form

§ Injectables

§ Oral Solids

§ Creams

§ Others

§ Key geographical regions

§ North America

§ Europe

§ Asia Pacific

§ Rest of the World

The “HPAPI and Cytotoxic Drugs Manufacturing (3rd Edition) 2020-2030” report features the following companies, which we identified to be key players in this domain:

§ AbbVie Contract Manufacturing

§ CARBOGEN AMCIS

§ Catalent

§ Evonik

§ Formosa Laboratories

§ Intas

§ Lonza

§ MabPlex

§ Pfizer CentreOne

Table of Contents

1. Preface

2. Executive Summary

3. Introduction